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Abstract:
Regulation of cell proliferation within an organism is a necessary and complex
process involving several proteins serving as controls at various cell cycle phases known
as cell cycle checkpoints. One of these checkpoints, the mitotic spindle checkpoint,
controls the advancement from metaphase to anaphase during mitosis and monitors the
proper attachment of the microtubules to the kinetochore. The spindle checkpoint
protein, BubR1 is a protein kinase that localizes to the kinetochores to monitor proper
microtubule attachment. BubR1 is able to inhibit the anaphase promoting complex
(APC) and delay the onset of anaphase. Concurrent with its role in regulating cell cycle,
mutations in BubR1 have been observed in various human cancers. In this work, we
examine the effects of BubR1 deficiency at the cellular and organism level using an
inbred mouse strain that is deficient for the BubR1 gene expression. We showed that the
complete loss of BubR1 resulted in an embryonic lethal phenotype and this phenotype
could not be rescued in a p53 deficient background. Additionally, mice heterozygous for
BubR1 showed a decreased life expectancy and an increased incidence of tumorigenesis.
Furthermore, our data indicates that the loss of BubR1 synergizes with p53 deficiency to
increase the susceptibility of cancer formation in mice and alters the tumor spectrum of
the p53 deficient mice. Finally we show that the BubR1 deficiency increases cellular
growth kinetics and transformation potential of MEFs derived from compound BubR1;
p53 mutants. This data provides insight into the importance of BubR1 in the prevention
of tumorigensis and its role as a checkpoint protein.
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I. Introduction:
Cancer Overview and Statistics:
Cancer is a disease of uncontrolled cell growth and division (1). In this disease, a
single cell, through mutation, becomes unable to monitor or control its proliferation. This
unchecked proliferation grants a growth advantage to the cell, and with time, allows
further mutations to accumulate within the cells created by the original cell, called clones.
These accumulated mutations will alter the clones in such a way that they are able to
escape regular growth control signals and, in some instances, develop the ability to
escape their primary site, referred to as a tumor, and spread throughout the body of the
organism (1). Mortality is often due to the fact that the rapidly dividing cells fail to
differentiate and perform the function they are designed to. Alternatively, these masses
can grow, affecting the normal functioning of adjacent organs or they can usurp the blood
supply to the normal tissue causing the organs near the mass to fail (2). Mammals have
evolved a variety of mechanisms to control/regulate cellular proliferation. However, over
time, these control mechanisms can become compromised due to accumulation of genetic
changes that result in uncontrolled cell growth.
Cancer is a disease prevalent world wide, and the loss of life and costs of
treatment have remained consistently high over the last 50 years, even though medical
advances have lowered the mortality and cost of many other commonly seen health
threats. Cancer can effect any organ or tissue type, but for the purposes of this study, we
will examine the trends of the disease overall and the statistics of colon/rectal cancer.
According to the American Cancer Society, in 2005, cancer was the second highest cause
1

of death with 22.8% of all deaths being attributed to cancer or its complications. Cancer
deaths are second only to heart disease which is the leading cause of death with 28.5% of
all deaths. The difference between the two, 5.7%, is relatively small especially when one
looks at the separation between the second and third leading cause of death,
cerebrovascular diseases, which accounts for only 6.7% of all deaths. This information
alone would be enough to promote a desire to understand this disease, but with the actual
number of deaths indicated, the need becomes more pressing. It is estimated that in the
US alone, 295,280 men and 275,000 women died from cancer in 2005. The leading type
of cancer for these people is lung cancer (31%), though cancers of the colon/rectum will
cost 10% of both men and women their lives, and are the third leading cause of deaths
from cancer. Also, it is estimated that 710, 040 men and 662, 870 women in the US were
diagnosed with new cases of cancer in 2005. Again, cancers of the colon/rectum will be
the third most common cancer to be diagnosed. According to these statistics, one out of
two men and one out of three women will develop cancer over the course of their lifetime
with one out of 17 of those, for both genders, being cancers of the colon. Also it has been
estimated that the cost of cancer in 2003 was $189.5 billion. Thus, it becomes apparent
that cancer is a disease in which discovering effective treatments to prevent or reduce
disease occurrence is an important step in promoting people’s health (2).

Cancer and the Cell Cycle:
Since cancer is a disease caused by uncontrolled cellular division, it is first
necessary to examine the way in which cell division occurs under normal conditions.
Cellular division consists of four stages. These stages are G1 (gap phase 1), S
2

(synthesis), G2 (gap phase 2), and M (mitosis). In G1, the cell has just finished a round
of cellular division and requires time to grow and obtain the nutrients and build the
proteins necessary to begin the next round of cellular division. Once the required needs
are met, the cell will enter S phase where the cell will replicate its DNA. DNA synthesis
is followed by a second gap phase where, again, the cell makes sure that it has time to
gather the necessary machinery to allow accurate and timely division as well as to assure
the integrity of the cell’s genetic material. Finally, during the M-phase, the cell
undergoes mitosis and completes cellular division. The cell cycle is conserved in all
dividing cells and is regulated by proteins known as cyclins and their partners, the cyclindependent kinases. (CDK). The CDKs are found constitutively in the cell during all of
the cell cycle stages. Cyclins on the other hand, are only expressed during the stage in
which they associate with their CDK partners. The cyclins then are ubiquitinated and
destroyed by the proteosome to allow progression into the next stage of the cell cycle (1,
3, 4). To facilitate the ubiquitination and subsequent destruction of these products, they
contain a conserved amino acid sequence of RxxLxxxxS. This sequence, known as the
destruction box sequence, is found in many cyclins as well as several other cell cycle
proteins that are regulated in a cell cycle dependent manner, such as BubR1. One way in
which normal cells develop a cancerous phenotype is through the improper activation or
production of these cyclins controlling the passage of the cell from one stage of the cell
cycle to the next (5).

3

Cell Cycle Checkpoints and Mitosis:
To assure the proper progression through the cell cycle, and to prevent the
progression to the next stage before the requirements of the previous stage are met, the
cell cycle has safeguards known as checkpoints. These checkpoints are found at critical
junctions of the cell cycle and allow the cell cycle to be arrested if there is DNA damage
or if the cell cycle progression stalls due to aberrant conditions. Upon activation of these
checkpoints, the cell will cease the cycle at whichever point it is in until the event that
activated the checkpoint is corrected for, allowing the cell cycle to continue. If the
situation is too dire, extended activation of the checkpoint will promote apoptosis. The
three commonly described cell cycle checkpoints are the checkpoints found at the G1/S
transition, which allows the cell to begin DNA replication, the G2/M transition, which
assures that the DNA was replicated without error, and the mitotic spindle checkpoint
which helps assure that there is accurate chromosome segregation (4, 6). A fourth cell
cycle check point is the intra-S checkpoint, which is activated when the replication fork
encounters DNA damage during replication. This checkpoint enhances genomic stability
by slowing DNA synthesis to allow time for DNA repair. (7)
The G1/S checkpoint is activated by DNA damage and will stall the progression
into S-phase by preventing the firing of the replication origins or progression of the
replication fork until the damage is repaired. This G1/S arrest allows for repair of the
template DNA and prevents DNA damage from becoming a fixed mutation in the cell for
subsequent divisions. The major players of the G1/S checkpoint include the proteins
ATM, ATR, p53 and p21 (8). In this checkpoint, DNA damage is sensed by ATM
Kinase and p53 protein levels are increased. The p53 tumor suppressor gene protein,
4

then activates several gene products leading to delay of the cell cycle progression (9).
Once the DNA damage is repaired, the checkpoint signal is reduced through the
destabilization and degradation of p53, and the cell is able to continue on to and through
S-phase.
After DNA replication, there is a second DNA damage checkpoint to assure that
both the template and the replicated DNA are undamaged. This occurs after replication
but before progression into mitosis and serves to assure that the daughter cells produced
both have DNA that is identical to the parent cell (4). The major components of the
G2/M checkpoint include Chk1, Chk2, and p53 proteins. If DNA damage is detected
during the G2-M transition phase, ATM or ATR will activate Chk1 and Chk2. These, in
turn, will phosphorylate and inactivate the phosphatase Cdc25c (10, 11). The role of
Cdc25C is to remove an inhibiting phosphorylation on Cdc2 (tyrosine-15). This
inhibition of Cdc2 stops the cell cycle from progressing into M-phase until the DNA
damage is repaired. The p53 protein is also activated by ATM or ATR in response to
DNA damage and serves a role similar here as in the G1/S checkpoint by inducing the
expression of p21 that arrests the cells at the G2/M phase. It is only after the progression
through these two checkpoints that the cell enters M-phase and subsequent cellular
division (6, 12).
Mitosis is a multi-step process in which the parent cell must condense its DNA
into paired chromosomes, align the chromosomes along the metaphase plate, accurately
separate the sister chromatids, and finally reform the nuclear membrane and de-condense
the DNA. The first step or stage of mitosis is known as prophase, and it is here that the
nuclear membrane breaks down and the DNA begins to condense. At this time, the sister
5

chromatids are secured together by proteins called cohesins, serving as molecular glue so
that they can eventually be divided equally between the two daughter cells. There is then
an intermediate stage known as prometaphase, where the chromosomes have condensed
and are free in the cytoplasm and the centrioles have reached the poles and begin building
microtubules. These microtubules will extend out into the cytoplasm and, upon making
contact, will bind to the kinetochore of the chromosomes. Eventually, at metaphase, the
microtubules will align the chromosomes up in the middle of the cell with the
microtubules attached to either side of the kinetochores. This places tension across each
kinetochore, signaling bipolar attachment. Once aligned across the metaphase plate, the
chromosomes then go through anaphase where the sister chromatids separate and move to
the poles. Once congregated at the poles, the chromosomes de-condense and the nuclear
membrane reforms around each set during telophase (figure 1). The cellular contents
then divide in a process known as cytokinesis and the two daughter cells are now formed
(1, 4).
It is during mitosis that we find the third cell cycle checkpoint, known as the
mitotic spindle checkpoint. In order to assure proper separation of the sister chromatids
to the daughter cells, the chromosomes must be aligned on the metaphase plate and each
of the chromatids must be attached to microtubules originating from opposing spindle
poles. Since the microtubules employ a “search and capture” method of attachment,
progression must be delayed until all of the chromosomes are attached and tension is
generated across the kinetochore, signaling bipolar attachment (13, 14). It has been
shown that the mitotic

6
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Figure 1: The stages of mitosis. This diagram shows the stages of mitosis. In prophase and
prometaphase the nuclear membrane breaks down and the DNA condenses. It is here that many
of the mitotic spindle checkpoint proteins will bind to the kinetochores of the chromosomes.
Once condensed, microtubules will attach to the chromosomes and line them on the metaphase
plate (metaphase) and upon alignment the sister chromatids will be separated and pulled towards
the poles (anaphase). Finally the chromosomes will reach the poles and de-condense and the
nuclear membrane regenerated and the cell will divide (telophase and cytokinesis). (images from
http://www.metu.edu.tr/~e118872/project/index.htm)
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spindle checkpoint signal is activated even if only a single kinetochore remains
unattached (15). The major components in the mammalian mitotic spindle checkpoint
include Mad1 and Mad2, Bub1, BubR1, and Bub3 (16). These proteins all localize to the
kinetochores of unattached microtubules during prometaphase and become activated
during metaphase, where they create a complex known as the Mitotic checkpoint
complex (MCC), along with the binding of Cdc20. Once the MCC is formed and
activated, believed to be through various phosphorylation events by the other checkpoint
proteins, the MCC then prevents the activation of the anaphase promoting complex or
cyclosome (APC/C) (17). The APC complex directs the ubiquitination of several
components including the protein securin. This degradation of securin allows its bound
partner, separase, to be released and cleave Scc1, a protein involved in keeping the sister
chromatids together during the early stages of mitosis. This frees the sister chromatids
from each other and allows the separation and movement of the chromatids to the spindle
poles. Also, the APC will ubiquitinate several of the mitotic proteins marking them for
degradation, allowing mitosis to end and the cell cycle to start anew (18, 19) (figure 2).

Role of p53 as a Checkpoint Protein:
Overview:
As mentioned above, cancer is a disease stemming from uncontrolled cellular
proliferation. In order to lose control of proliferation mutation in key cell cycle
components or their checkpoints are necessary. It is interesting to note that the most
commonly mutated gene in human cancers is p53. As previously stated, p53 serves as a
checkpoint in both the G1/S and the G2/M phases. This makes p53 an ideal protein for
8

Figure 2: The mitotic spindle checkpoint. This diagram shows the role of BubR1 as well as other
spindle checkpoint proteins in the activation of the mitotic spindle checkpoint. In prometaphase,
unattached kinetochores will allow the localization of multiple checkpoint proteins including
BubR1 and Mad2. Once localized and activated (believe to be through phosphorylation events)
these proteins interact with Cdc20 to inhibit the APC. Once attachment and tension is signaled
these checkpoint proteins become inactive and the APC is no longer inhibited and anaphase
begins (20).
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cancer study since insights on the mechanisms of p53 mediated cell cycle control could
serve as the foundation for new or more effective cancer treatment strategies.
The gene product of p53 is a protein of ~53 kDa that is made up of three domains.
These domains include an activation domain at the amino-terminal spanning residues 142, a central core containing the sequence-specific DNA-binding domain spanning
residues 100-300, and finally a carboxyl-terminal, multi-functional domain spanning
residues 300-399. Each of these domains connects through a flexible linker sequence
(21). In the protein, there are five evolutionarily conserved regions with the first one
being in the N-terminal activation domain and the other four found in the central
core. Multiple phosphorylation sites are found in both the N-terminal and C-terminal
domains, which are used to regulate the activity of p53. (22)

Activation of p53:
After exposure to DNA damaging agents, multiple forms of DNA damage are
induced that include double strand breaks and base alterations. This damage leads to the
activation of p53 through the actions of multiple kinases that phosphorylate p53 at
multiple sites. The kinases involved in this response include JNK, ATM and ATR (10,
11). In addition to the phosphorylating events at serines 15, 20, and 37, there is also a dephosphorylating event at serine 376 which opens a new site in p53 for interaction with
the scaffold protein 14-3-3 (8, 23, 24). Phosphorylation of the above serines, stabilize the
protein and inhibit its interaction with the negative regulator protein Mdm-2. Once
stable, p53 is transported into the nucleus via phosphorylation of serine 392 by CK II
where it tetramerizes and exhibits its transcriptional activity (25-27). Unlike the rapid
10

response seen to ionizing radiation, DNA damaged induced by UV has a slower response
time. Since the damage caused by UV is most often the formation of bulky lesions such
as thymidine dimers there is no immediate detection of the lesion until the replicative or
transcriptional machinery stalls upon reaching the lesion. Once the damage is detected;
the stalling of RNA polymerase II causes serine 33 on p53 is phosphorylated by the CDK
Activating Kinase (CAK) from TFIIH. Additionally, ATR activates Chk I and Chk II
which phosphorylate serine 20 while ATR directly phosphorylates serine 15 and 37 (28).
As seen above in response to ionizing radiation, these phosphorylation events, lead to the
stabilization of p53. Once stabilized, p53 is again phosphorylated on serine 392, and
transported into the nucleus where it tetramerizes and induces the transcription of the
DNA damage response genes (29). The various phosphorylations of p53 lead to the
alteration of the protein structure and expose the central core’s sequence-specific DNAbinding domain as well as allowing the N-terminal activation domains to interact with
other transcriptional factors such as TATA box-binding protein (TBP) and its associated
factors (TAFs) (30) . Finally, since p53 accumulation will sequester the cofactors
involved in transcription, those genes that do not contain a p53 specific binding site will
not be transcriptionally active until the level of p53 is restored to its base (31-34).

Physiological role of p53:
The activation of p53 leads to three outcomes for the cell; cell cycle arrest,
cellular senescence, or apoptosis. By keeping with these outcomes, p53 is able to protect
the genome from accumulating mutations. However, since these effects prevent cellular
growth, p53 must be tightly regulated to prevent wasteful delay, arrest and/or
11

unnecessary apoptosis. In many organisms, the extensive loss of cells due to up
regulation of p53 can lead to problems which can put the entire organism at risk. On the
other hand, if p53 is too tightly regulated due to an over-expression of its negative
regulators or an under-expression of the gene itself, the stability of the genome can
become uncertain due to the lack of p53-dependent checkpoint activation. Once
activated, the results of the activation must be decided as to whether the cell undergoes
cell cycle arrest or apoptosis. This decision is based on several factors including the cell
type, severity of damage, and the time that p53 activity was induced.
Most of the genes induced by p53 lead to several outcomes that include cell cycle
arrest, apoptosis, and cellular senescence. An example of p53 induced cell cycle arrest is
the induction of the p21 gene whose product promotes cell cycle arrest in G1/S through
binding and inhibition of the CDKs necessary for cell cycle progression. Activated p53
has been shown to bind to the p21 promoter. This binding increases transcription of the
gene product and p21 will then form part of a quaternary complex with PCNA and the
cyclin/CDK complex. This quaternary complex will inhibit the cyclin/CDK activity,
arresting the cell cycle in G1. In addition to p21, after ionizing radiation, p53 will also
bind to the promoter of GADD45 (growth arrest and DNA damage inducible gene) and
activate it. This protein will then interact with PCNA, a replication and repair factor and
inhibit it. With the inhibition of PCNA the cell will be unable to enter S-phase and the
cell cycle comes to a halt. Also, it has been shown that GADD45 is able to alter the
chromatin accessibility which could inhibit progression into S-phase by maintaining the
DNA in an inaccessible form to other replication factors until the damage is repaired (22,
26). In some cell types, activation of p21 by p53 leads to prolonged cellular arrest.
12

Dependent on the damage or the cell type, the activation of p53 may induce
apoptosis (35). This pathway begins similar to the cell cycle arrest pathway in that p53 is
activated, stabilized, and transported into the cell nucleus. However, from here things
become a bit less characterized. While it is known that p53 mediated cell cycle arrest
requires the protein’s transcriptional activity, initial reports seemed to indicate that the
transcriptional activity may not be necessary and it was suggested that p53 may have both
a transcription dependent and independent pathway to induce apoptosis. (22) However, a
later work showed that the induction of apoptosis through p53 is a three step process
which requires p53 to be transcriptionally active. From this study it was determined that
upon the activation of p53, a subset of genes known as the p53 inducible genes (Pigs) are
promoted. The transcription of these genes, which code for several proteins involved in
regulation of reactive oxygen species (ROS), will lead to an increase in the level of ROS.
This increase of the ROS level will then work to decrease the stability of the
mitochondrial membrane that leads to Cytochrome-C release. Once released,
Cytochrome-C will interact with several other apoptotic proteins ultimately leading to the
activation of the caspase cascade that will induce genomic degradation and membrane
blebbing, hallmarks of apoptosis.

Regulation of p53 activity
As seen from the information presented already, the regulation of p53 is
tightly controlled and the activating cascade requires several players to properly stabilize,
activate and localize the protein so that it may exert its effect. In addition to these
activating proteins, p53 is also regulated on its transcriptional and translational levels.
13

Transcriptionally, p53 is induced in response to the stress factors such as AP-1, NF-kB
and Myc/Max as well as the products of YY1 and NF1. These transcription factors will
bind to the promoter of p53 and promote transcription of the gene (36). The p53 gene is
transcriptionally repressed by the Pax transcription factor family (37). Also, the viral
protein Tax and the over expression of c-Jun have been shown to repress transcription of
p53(38, 39). During the translation of the p53 mRNA, p53 has been shown to be able to
repress its own translation through the 3’ untranslated region (UTR) in human and the 5’
UTR in murine p53. These UTR sequences can form stable secondary structures which
can repress translation through interaction with the RNA binding factors.
Though p53 is regulated both in its transcription and translation, the majority of
its regulation is seen post-translationally. In the cell, cytoplasmic p53 has a short lifespan
of only a couple minutes. The protein p53 can induce the transcription of proteins which
attenuate its activity serving as an auto-regulatory feedback. An example of this is the
mdm-2 gene, whose protein product binds to p53, preventing its nuclear localization and
promoting its degradation, is a downstream target of p53 (22, 25, 31). Thus p53 upregulates its own inhibitory factors, thereby assuring that p53 activity will diminish
quickly after the DNA damage is repaired (40). Cytoplasmic p53 is bound to the protein
MDM-2 and ubiquitinated, targeting the protein for degradation by the 26s proteosome
(41, 42). In addition to this degradative pathway to regulate p53, the localization of p53
is another way of controlling p53 activity. For p53 to function, it must first be able to
enter the nucleus of the cell. To do this, p53 has a nuclear localization signal which must
be accessible to recognition sites on the nuclear membrane and so one method of
regulation is via the binding of other proteins which hide the signal. One example of this
14

is the binding of p53 to Mdm-2 to prevent access of the localization domain. Also, once
imported into the nucleus, p53 may bind to MDM-2 and be subsequently exported. By
controlling the degradation or localization of p53, the cell assures that any protein present
in the cell remains at sub-active levels until activation and stabilization of the protein is
needed (22, 25).

Effects of p53 Inactivation:
With p53 serving such an important role in maintaining genomic stability and
providing the means to arrest cell cycle progression or promote apoptosis, it is no small
wonder that mutation of p53 or the complete loss of the gene is commonly seen in cancer.
The most commonly seen mutations of p53 are found in the DNA binding regions of the
protein. These mutations all serve to prevent p53 from inducing the transcription of cell
cycle arrest or apoptotic genes (31). Additionally, mutations of the NLS region of the
protein have been characterized. It has been observed that mutation of the NLS region or
alteration of the residues lysine 305 and arginine 306 leads to the cytoplasmic
localization of p53 and its inactivation (25). Finally, mutation of either p53 or MDM-2 to
prevent their dissociation will lead to a substantial reduction of inducible p53 which will
prevent p53 mediated cell cycle arrest or apoptosis (34). In all of these mutations, the
inactivation of p53 leads to increased proliferation, genomic instability, and the
accumulation of mutation due to the loss of cell cycle arrest and apoptosis.

15

Role of BubR1 as a Checkpoint Protein:
Overview
The protein, BubR1, is a part of the mitotic spindle checkpoint which serves to
assure anaphase delay until the chromosomes are properly aligned on the metaphase plate
with proper microtubule attachment and tension along all the kinotechores. The human
BubR1 gene is located on chromosome 15q15 and its product is considered to be one of
the major players in the prevention of chromosomal instability (CIN). While BubR1
mutations are not prevalent in all cancers, studies have shown that mutations of BubR1 do
occur in some colorectal cancers. (43) In addition, chromosomal rearrangements of
15q15 have been observed in some leukemias. These rearrangements may promote the
inactivation of BubR1 as a checkpoint control protein and increase the likelihood of
tumor progression (44). BubR1 is a gene found in mammals but not in yeast and has
homology to both yeast genes BUB1 and MAD3, hence the names BubR1 (bub1-related).
BubR1 was first identified in a study by Davenport et al. using differential expression of
normal and leukemic mouse thymocytes. In this study, a homologue to the yeast
checkpoint protein Bub1 was discovered and this novel family member, named mBub1b,
was shown to have 40% sequence similarity to murine Bub1a over 4 extended domains.
To better understand this novel protein, Davenport et al. used the clone fragment B13
from their differential expression studies to isolate a 3,647 base pair cDNA from the 16
day mouse embryo cDNA library and determined some of the properties of this new
protein (44). As mentioned above, the BubR1 gene transcribes a message of 3,647 base
pairs making up 23 exons with a promoter located 1,368 base pairs upstream of exon 1.
It was also found that a GC-rich region rests 150 base pairs upstream of exon 1. This
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translates to a protein with 1,052 residues across four major domains. These domains are
a Ken-box motif, a signaling sequence for degradation, (residues 26-28), a Mad3-like
region (residues 52-204), a Bub3 binding domain (residues 392-433) and a kinase domain
(residues 749-1018) (45). The kinase domain of BubR1 is atypical in that the kinase
domains of Bub1, BubR1 and the yeast Bub1 are more closely related to each other than
to other kinase domains. Even with this being the case, BubR1 contains significant
alterations which mask its relationship to other kinases outside of the bub family. An
example of this is the substitutions of Bub1’s Glutamate 127 and Aspartate 170 with
BubR1’s Asparagine and Arginine (44). These alterations are explained in Davenport’s
work as proofs that BubR1 has different substrates than Bub1. Along with these
domains, BubR1 has a destruction box sequence immediately following its aminoterminal domain, (residues 222-230 in the mouse Bub1b) and two sequences that could
serve as nuclear localization signals (residues 229-234 and 412-117) (44). Also, later
work showed that BubR1 contained a dileucine motif (residues 958-963) this motif is
commonly seen as an adaptor beta chain recognition motif (46). The destruction box
sequence, RSSLAELKS, is located between the Mad3-like and the Bub3 binding
domains and serves to promote degradation of the protein through ubiquitination of the
lysine residues targeting the protein for destruction by the proteosome. This destruction
box allows the degradation of BubR1 in a cell cycle-dependent manner (44, 47). Along
with these various sequences and within these domains are several phosphorylation sites.
These sites are hypothesized to serve as activators and regulators for BubR1 activity in
the event of mitotic spindle checkpoint activations (figure 3).
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Figure 3: The BubR1 protein. This diagram shows the BubR1 protein and its evolutionarily
conserved domains as well as their role in the activity of BubR1. The Destruction box (DB) is
located just past the N-terminal domain of the protein (containing its Mad3 like region and Ken
box motif). The nuclear localization sequence (NLS) is located within the kinetochore binding
domain.
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Functional role of BubR1:
As implied by its multiple structural domains and motifs, the role of BubR1 in the
cell is complex. The exact function and binding partners as well as the kinase substrates
of this protein have been sought out since it was first isolated in 1998 (43, 44). Many
researchers have spent years on this gene and while strides have been made and some of
its key roles determined, there is still a great deal to learn about this gene and its product.
The isolation and study of BubR1 done by Davenport determined that the product
was expressed in all dividing cells and highly expressed in the spleen and thymus. This
work showed that expression of this gene peaked around the G2/M phase of the cell cycle
and due to its homology to Bub1, it was determined that BubR1 has a distinct role in the
mitotic checkpoint. This finding was confirmed in a separate study by Cahill et al. who
examined 19 colorectal cancer cell lines that exhibited chromosomal instability (CIN)
and found that in two of them there was a mutation of the human bub1 homologue
BUBR1(43, 44). One of the first studies to determine BubR1’s binding partners and
regulation was done by Chan et al examining the interaction of BubR1 with the
centromeric motor protein E (CENP-E). It was found that while BubR1 levels were
lowest in G1, it steadily increased towards mitosis. During Mitosis, BubR1 was hyperphosphorylated and it was found that this hyper-phosphorylation increased the kinase
activity of the protein (48, 49). Their studies also showed that BubR1 was capable of
binding to CENP-E in the cytoplasm of interphase cells through interactions of 641
residues at its C-terminal. Furthermore it was observed that BubR1 could localize to the
kinetochores of unaligned chromosomes during prometaphase. This localization would
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occur after the localization of CENP-F but before the localization of CENP-E suggesting
that BubR1 may phosphorylate substrates on the kinetochore to allow the binding of
CENP-E. Because it was accepted that BubR1 had a distinct role in the mitotic
checkpoint and this discovery that BubR1 interacted with CENP-E, a motor protein, it
was suggested that the BubR1/CENP-E complex served as a mechanosensor for the
unaligned chromosome (49). Later experiments were able to show that BubR1 was an
essential component of the mitotic checkpoint though CENP-E was not. Additionally,
the kinase activity of BubR1 was examined and it was observed that while BubR1 had no
detectable kinase activity in either interphase cells, or in mitotic checkpoint activated
cells, through addition of the drug nocodazole, BubR1 showed a high level of kinase
ability both for itself as well as a number of exogenous substrates using in vitro kinase
assays. It was determined that one role of BubR1 was to prevent normal mitotic exit until
the chromosomes had aligned properly and this arrest was through specific interactions
with the Anaphase Promoting Complex (APC). In addition to this role in the mitotic
checkpoint activation, it was confirmed that BubR1 served to monitor functions specified
by CENP-E as a tension checkpoint (48). In 2001, in a study by Skoufias et al. it was
confirmed that one of the major roles of BubR1 was to sense tension across the
chromosome’s kinetochore. It was shown that in the event of tension loss while
microtubule attachment was maintained, Bub1 and BubR1 returned to the kinotechore to
delay anaphase until tension was restored. It was suggested that BubR1 and another
mitotic checkpoint protein Mad2 were parts of two distinct checkpoints, one sensing
tension and the other sensing microtubule attachment (50). However, this model was
later proven to be incorrect through a study by Shannon et al. when it was shown that in
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cell lines under hypothermic conditions, the major cause of prometaphase delay due to
lack of tension, that the mitotic delay could be attenuated either through the addition of
antibodies against Mad2 or BubR1. Additionally, it was observed that the addition of
both antibodies did not accelerate the progression into anaphase. This showed that
BubR1 and Mad2 were components of the same checkpoint pathway (51). Other
researchers were able to provide insight into the function of BubR1 showing that once
localized to the outer kinetochore plate, BubR1 binds to CENP-E and Bub3 (20, 52).
This localization event is dependent on the previous localization of Bub1 and in the event
Bub1 is missing or unable to bind to the kinetochore, the amount of BubR1 localized to
the kinetochore is greatly reduced. Finally, it was observed that BubR1 must first interact
with Bub3 before it could bind to the kinetochore (53, 54).

BubR1 activation and mitotic spindle checkpoint:
In the event of tension loss or microtubule instability during mitosis, BubR1 is
hyper-phosphorylated and becomes active. This phosphorylation event is facilitated by
Mad1 on the kinetochore and serves to alter BubR1 in such a way that it is able to interact
directly with the APC as part of the mitotic checkpoint complex made up of the other
checkpoint proteins Mad2 and Bub3 along with the APC cofactor Cdc20 or its subcomplexes (55). Without the presence of Mad1, while still on the kinetochore, and
Mad2, BubR1 would not be able to interact with Cdc20 (53). This interaction inhibits the
activity of the APC by preventing meaningful interactions between the APC and its
substrates (20, 45, 52, 53). In all of these studies, it was shown that the BubR1 kinase
domain was not necessary for the direct stoichiometric binding of BubR1 or the mitotic
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checkpoint complex (MCC) to inhibit the APC. In addition to direct binding of the
MCC to inhibit the APC, Yoon et al. observed that BubR1 was able to phosphorylate
Cdc20 in vitro and that this phosphorylation event prevented the interaction between
Cdc20 and the APC, effectively leading to a metaphase/anaphase block (45).

Additional functions of BubR1:
Another checkpoint protein phosphorylated by BubR1 is the breast cancer
susceptibility gene BRCA2. The downstream effects of this phosphorylation event are
still not clear but it is suspected that this allows interaction of BRCA2 with its substrates
leading to cell cycle arrest (52). In a study by Shin et al., it was suggested that the role of
BubR1 activation may not just lie in its activities during spindle checkpoint activation but
also that the prolonged activation of the spindle checkpoint through BubR1 could
promote apoptosis in those cells that eventually adapted to the arrest and exited mitosis,
effectively executing a “fail safe” mechanism to prevent the propagation of cells
breaching the mitotic checkpoint. This induction of apoptosis was found to be through
the intrinsic pathway and the activation of caspase-9 leading to the subsequent activation
of caspase-3 and apoptosis. A study by Vogel et al. further showed that cells need a
functional mitotic checkpoint to activate post mitotic G1 arrest (56). Finally, Lens et al.
found that for BubR1 to sustain its activity during prolonged checkpoint activation, the
protein Survivin was necessary. It was also suggested that BubR1 was a possible
substrate for Aurora B Kinase (47, 57). In addition to its role in the Spindle checkpoint,
BubR1 has been found to interact with Beta2-adaptin, a subunit of AP2, on its N-terminal
“trunk” domain and the C-terminal kinase domain of BubR1. AP2 is a member of the
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assembly protein family involved in vesicular transport through the cell. AP2 mediates
rapid endocytosis of the plasma membrane. It was found that BubR1 is able to interact
with B2-adaptin through out the cell cycle suggesting that BubR1 might have a novel role
in the regulation of vesicular intracellular traffic by regulating the soluble pools of B2adaptin (46). Finally, in recent work by Fang et al. it was observed that MEF cell lines
deficient for BubR1 exhibited compromised mitotic arrest and DNA repair after DNA
damage by UV or the drug doxorubicin. DNA repair was found to be compromised in
these cell lines through the down-regulation of p53, p21, phospho-H2AX and the
enhanced degradation of PARP-1. Taken together this strongly suggests that a
deficiency of BubR1 leads to continued cell cycling even after exposure to DNA
damaging agents and through the down-regulation of key components of the DNA
damage repair pathways, allows for the increased possibility of DNA damage and
tumorigenesis (58)

Effects of BubR1 inactivation:
As it has been shown, BubR1 is an important component of the spindle
checkpoint and has shown promise to play a role in several other checkpoints and cellular
functions as well. BubR1 became a gene of interest due to the fact that mutant forms of
the gene were observed in two colorectal cancer cell lines and that these cell lines
exhibited chromosomal instability. From this it was suggested that the aneuploidy seen
in cancer was due to the loss of chromosomal stability and that this loss was reflected
through the mutation or loss of BubR1 (43). The idea that mutation in BubR1 caused
chromosomal instability and its mutation was a factor in tumorigenesis was supported by
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the work of Oshima et al who found that in four T-cell leukemia/lymphoma cell lines,
BubR1 was found to have two missense mutations, one nonsense mutation, and an
internal deletion (59). Furthermore, in breast cancer patients the aberrant expression of
the protein encoded by the breast cancer specific gene 1 (BCSG1) has been shown to
target BubR1 for degradation (60).
With the ability to create knock-out mice using the gene trapping method, BubR1
haplo-insufficient mice were able to be bred to examine the effects of the loss of one
BubR1 allele. By pairing mice both missing one functional allele of BubR1, it was
determined that BubR1 was an essential gene and that embryos nullizygous for BubR1
begin to die 6.5 days after conception and that by 8.5 days, the nullizygous embryos are
all reabsorbed. It was also determined that this embryonic death was due to extensive
apoptosis (61, 62). The heterozygous mice lived well into adulthood but still exhibited
problems and increased susceptibility to carcinogens. It was found that the spleens of
heterozygous mice were enlarged with an increase in the number of mature
megakaryocytes. These mice exhibit anemia and defects in platelet formation. It was
hypothesized that this increase in spleenic megakaryocytes was due to the loss of proper
cell division that in turn resulted in the formation of multinucleated megakaryocytes (62).
It was also observed that mice heterozygous for the BubR1 gene trap were prone to
tumors after exposure to azoxymethane, a known colon carcinogen. Heterozygous mice
exposed to carcinogens develop colon masses two months after exposure while those
with both functional alleles did not develop masses until six to eight months after
treatment. It was also found that the heterozygous mice also developed tumors of the
lung and liver, that was not observed in the wild-type mice (61). Later, Baker et al were
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able to produce a hypomorphic mouse that expressed only 11% of the wild-type BubR1
level (BubR1 heterozygous mice express ~25% of wild-type levels). These mice were
able to survive to adulthood but showed severe phenotypes including cachexia and
lordokyphosis from three to six months of age and had a median lifespan of only six
months, compared to the approximate two years observed in wild-type mice. These mice
were also found to be infertile. Embryonic fibroblasts of BubR1 hypomorphic mice
showed a severely compromised spindle checkpoint and a high level of aneuploidy. It
was suggested in this study that BubR1 had a role in aging as those mice hypomorphic
for BubR1 exhibited symptoms of advanced age (63). In work done by Rao et al. it was
observed that BubR1 insufficiency had a synergistic effect with other proliferative
control genes in the progression of tumorigenesis. It was observed that in a mouse strain
exhibiting a mutation of the adenomatous polyposis coli gene (Apc), the introduction of
BubR1 insufficiency led to a ten fold increase in the incidence of tumors in the colon. It
was also seen that these tumors were in advanced stages of development. It was
hypothesized that this increased tumor incidence was due to the role BubR1 played to
prevent chromosomal instability. (64)

Rational for Generating BubR1/p53 Compound Mutants:
In this study, we have analyzed the synergistic effects of p53 deletion in the
tumorigenesis in mice deficient for BubR1. Studies have shown that cancer is a multistep process that requires the inactivation of a variety of gene products involved in
proliferation control. Furthermore, Fearon and Vogelstein and colleagues have shown
the necessity for p53 inactivation in human colon cancer patients (65). Based on these
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observations we hypothesized that the additional inactivation of the p53 tumor suppressor
gene will either enhance the tumor susceptibility, indicated by a decrease in the lifespan,
of the BubR1 mutant mice and/or induce the formation of colon cancer. To measure
tumor susceptibility we generate a compound mutant for BubR1 and p53 and monitored
the colony for a period of two and a half years.
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II. Materials and Methods:
Generation of BubR1 Mutant Mice in a p53 Deficient Background:
In order to study the role of BubR1 in the spindle assembly checkpoint and cancer
formation, BubR1 deficient mice were generated using embryonic stem (ES) cells
obtained from the Mutant Mouse Resource Center at UC Davis. A gene trap approach
was used to achieve disruption of the BubR1 gene as described earlier (66). The gene
trap, containing a splice acceptor and an ATG-less betagalactosidase-neomycin fusion
cassette, was determined to have inserted into intron 2 of the BubR1 gene. The genetrapped ES cells, from the 129P2/ OlaHsd strain, were analyzed by PCR and Southern
blotting to confirm the presence of the trap within the BubR1 gene. Upon confirmation,
the mutant ES cells were used for injection into 3.5 day old blastocysts and implanted
into a pseudo-pregnant c57 bl/6 mouse. Nine chimeric mice were generated from these
blastocyst injections and of these, four founder males produced germ line litters for the
BubR1 deletion as detected by the agouti coat color. Tail clips were taken from the first
two litters for genotype analysis. These analyses indicated equal numbers of wild type
and heterozygous offspring consistent with the expected Mendelian ratio. Additionally,
the heterozygous mice had no recognizable developmental defects. Heterozygous F1
offspring from the chimera males were then crossed in an effort to obtain BubR1
nullizygotes. To generate compound heterozygotes, the BubR1 mutant mice were
crossed to our p53 deficient mouse strains (67).
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DNA Extraction:
To obtain DNA from our mice for Southern blotting and PCR based genotyping,
we first took tail clippings from the pups during weaning and incubated each tail
separately in 500 µl of tail lysis buffer (50 mM Tris ph 7.5, 50 mM EDTA, 100 mM
NaCl, 1% SDS) along with 10 µl of Proteinase K and 1.25 µl 2M DTT. These tail
clippings were then incubated overnight at 55-60 degrees Celsius. After incubation, 500
µl of phenol: chloroform (24:1) was added and the contents were mixed well. The
lysates were then spun in a microcentrifuge for three minutes at 13,000 rpm.
Approximately 400 µl of the top layer (the aqueous phase) are removed into a second
tube. After collecting the aqueous phase, twice the volume (800 µl) of 100% ethanol is
added to each sample. Genomic DNA was precipitated out of solution and spooled out
and placed into a third tube containing 50-100 µl of 5 mM Tris (10mM Tris, 1mM
EDTA) depending on the amount of DNA recovered. DNA was solubilized overnight
and concentrations determined for use in southern blotting and PCR genotyping.

BubR1 Genotyping:
To determine the BubR1 genotype, we employed a PCR based strategy. For each
sample, 200 ng of DNA was added to 23 µl of a PCR master mix (containing 1X PCR
Buffer, 1.5 mM MgCl2, 0.2 mM dNTP (each), 0.2 µM of the forward and reverse
primers, 1.0 unit of Platinum Taq DNA Polymerase). The PCR conditions for the
insertion and wild-type PCR were as follows: an initial two minute denaturation step at
94oC, followed by another denaturation step for 30 seconds at 94oC, annealing for 30
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seconds at 54oC followed by an extension step for 135 seconds at 72oC. The second
denaturation, annealing, and extension steps were repeated for 32 cycles and then a final
five minute extension step at 72oC. For the Trap PCR the conditions were essentially the
same with a decrease in extension time (75 seconds). The primers used to determine if
the trap was located in the DNA were TR2 (5’CAACACTTGTATGGCCTTGGCG-3’)
and TR3 (5’GTGAGCGAGTAACAACCCGTC-3’). This created a PCR product of 665
bp and verified that the trap was located in the sample. To determine the proper insertion
of the gene trap, the primers GS1 (5’TTGGCAAAGCAAGAGTCAGC-3’) and TR1
(5’CCCAACTGACCTTGGGCAAGAACATA-3’) were used, creating a PCR product of
2.4 kb. These two products together verified the presence and proper insertion of the
gene trap in our BubR1 gene. To determine if the wild-type allele was there we used the
primers GS1 and GS2 (5’CCAGCCTAGGATACTTGGAGA-3’). This produced a PCR
product of 2.2 kb and indicated the presence of the undisturbed intron.

Generation of Mouse Embryonic Fibroblasts (MEF):
Compound heterozygous crosses were performed and the pregnant female
sacrificed at embryonic day 13.5 and the embryos removed and placed into separate 15
ml test tubes. Using a two ml syringe with a small bore needle, the embryo was placed
into the syringe and pressed through the needle into cell media (DMEM, 15% FBS, 10
units of Pen/Strep). The cell suspension was then added to 2 large plates and incubated
for two to three days. Once confluent, the plates were split 1:3 and allowed to grow until
confluent and then split again at a ratio 1:3. A portion of the cells were isolated and used
for experiments, while the rest of the cells were frozen in liquid nitrogen.
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Cell Proliferation Assay:
Cell lines at the same passage were removed from liquid nitrogen storage and
plated on 60 mm culture plates in media (DMEM, 15% FBS, 10 units of PenStrep). At
90% confluence, cell were trypsinized, and re-plated, onto a 100 mm plate, and allowed
to grow to 80% confluence. Once confluent, these plates are then trypsinized and
counted (to count the cells, 50 ul of the collected cell suspension was added to 100 ul of
PBS/EDTA and from that mixture 50 ul of the solution was placed onto a hemocytometer
and the four blocks counted, divided by four and multiplied first by the dilution factor
and then by 10,000 to get the number of cells per milliliter of cell suspension) and
125,000 cells are seeded onto two 6-well plates and allowed to grow for one day. On day
two and each of the following five days, two wells from each cell line are trypsinized and
counted. These numbers are then plotted.

Colony Forming Unit Assay (CFU):
Cell lines were removed from liquid nitrogen and seeded onto 60 mm plates with
media (DMEM, 15% FBS, 10 units of PenStrep) and then passage on a three-day/fourday cycle until passage six, seeding 400,000 cells each time. At passage six, the plates
were trypsinized and counted and 400,000 cells were passaged on to passage 12 where
the second part of this study was done.
At passages six and twelve, 2,500 cells were seeded onto each of four small plates
and allowed to grow for nine days with media changes every three days. After this
growth period, the media was removed from each plate, rinsed with PBS, and 100%
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methanol was added to each plate to fix the cells for nine minutes. After fixing the cells,
Giemsa stain (1.25 ml Giemsa stain, 1.5 ml 100% Methanol, QS to 50 ml) was added to
cover the cells and allowed to incubate for 9 minutes. After this incubation, the stain was
removed and each plate was rinsed twice with distilled water to remove any access stain
remaining in the plate. After drying, colonies consisting of 40 cells or more were
considered in the colony count.

Cell Cycle Analysis:
Low passage MEFs cell lines were seeded on to 35 mm tissue culture plates (300,000
cells/plate) and were allowed to grow for ~24 hours before the addition of the spindle
poison, nocodazole (125ng/ml). Cells were trypsinized at various time points (8, 24 and
48 hours) and collected by centrifugation. Single cell suspensions were prepared from
the cell pellets using a vortex, fixed in 70% ethanol, and stored at -20oC until the DNA
content could be examined via flow cytometry for each genotype.

Animal Husbandry:
Mice were housed in small sterilizable cages with isolation lids and fed ad lib. At
21 days, pups were weaned and a tail clipping was taken for DNA extraction. In this
controlled environment, mice were examined 3 times weekly for signs of illness or tumor
formation. In the event a mouse was found to exhibit morbidity or have developed a
palpable mass, it was euthanized using carbon dioxide and dissected. During autopsy,
tumor tissues and organs exhibiting abnormal morphology were removed and a sample of
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it was formalin-fixed and another sample was removed and stored at -80oC to be used for
genotyping.

Southern Blotting:
To determine the p53 genotype of the mice, southern blot assays were performed.
Genomic DNA (3 µg) from the tail clipping was digested with Bam HI overnight at 37oC.
The next day the samples were subjected to electrophoresis, buffered in tris-acetateEDTA (40mM tris base, 20 mM acetate, 2mM EDTA) and imaged. After imaging, the
membrane was washed in 0.25 M HCl for 5 minutes, rinsed 4 times with distilled water
and transferred onto a nylon membrane overnight using 0.4 N NaOH. Following DNA
transfer, the membrane containing the blotted DNA was rinsed with 2X SSC, dried at
37oC and blocked with pre-hybridization buffer (1.3% SDS, 2X SSPE, 1% milk, and 2
mg denatured salmon sperm DNA) for 5 hours at 68oC. After blocking, the prehybridization buffer was removed and 20 ml of hybridization buffer was added (10%
dextran sulfate, 1.5X SSPE, 1% SDS, 0.5% milk) along with the radio-labeled probe.
(1x106 cpm/ml). After incubating overnight, the hybridization buffer was removed and
the membrane was rinsed with 2X SSC followed by a series of solutions (Solution 1: 2X
SSC, 0.1% SDS. Solution 2: 0.5X SSC, 0.1% SDS. Solution 3: 0.2X SSC, 0.2% SDS).
Once the membrane activity is between 2,000 and 3,000 counts per minute, the
membrane was exposed on x-ray film overnight at -80oC. This was to reduce the amount
of nonspecific binding of the radioprobe to the membrane, allowing for clearer results.
The radio-labeled probe was generated using 100ng of DNA specific to exons 2-6 (a 600
bp fragment from the Kpn I digested plasmid (LR10) containing murine p53 cDNA) of
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the p53 gene. This probe was then labeled with dCTP[α-32P] using random primers. The
specific activity of the radiolabel was 3,000 Ci/mmol. In addition to the two possible
bands that represent the wild type and mutant alleles, the p53 probe also binds to
pseudogene regardless of the p53 genotype (figure 4).
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Figure 4: Southern blot results indicate the p53 genotype. An image of the southern blot with the
bands labeled for 6 samples (from genomic DNA extracted from the tails of mice). The top band
is a pseudogene, the middle band indicating the mutant allele (in which a small portion of exon 5
was deleted and a neomycin fusion cassette inserted) and the bottom band indicates the presence
of the wild type allele.
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III. Results:
Characterization of the BubR1 gene Trap Insertion Site:
The 5’ RACE data obtained from the Mutant Mouse Regional Resource Center
(MMRRC) indicated that the trap had inserted into intron 2 of the gene. Using this data,
we designed primers specific for exon 2 of BubR1 (GS1) and the gene trap (TR1). PCR
amplification produced a 2.4 Kb fragment that was specific only to the trapped allele (as
determined by the trap-specific PCR primers TR2 and TR3). Sequence analysis of the
PCR product revealed that the trap had inserted into intron 2 of the BubR1 gene at base
2,170. Integration of the trap also resulted in the loss of the first 880 base pairs within the
trap. However, this did not affect the function of the trap since the splice acceptor lies
outside these lost bases (~1,276). Based on this information, we designed primers
adjacent to the insertion site to amplify a 2.2 Kb fragment specific for the wild-type
allele. A schematic representation of the primer sites with respect to the gene trap are
shown in figure 5. An example of the PCR products obtained for various combinations
of primer pairs is shown in figure 6.

BubR1 Deficiency Affects Embryogenesis:
We generated F1 heterozygotes using male chimeras and wild type females. The
BubR1 heterozygotes developed normally and were capable of producing progeny. In
order to generate mice that were completely deficient for the BubR1 allele we
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Figure 5: The BubR1 gene and the location of the PCR primers. This schematic representation of
the wild-type and trapped alleles show the positions of the PCR primers used for genotyping. In
addition to this the blue triangle indicates the location where the gene trap inserts into the BubR1
gene.
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Figure 6: PCR indicates the BubR1 genotype. This gel image provides BubR1 genotype data for
5 samples. The marker here is a 1 kb+ ladder. The trap PCR used the primers TR2 and TR3
from the schematic above while the Insertion and wild type PCRs used the primer GS1 and either
TR1 (the insertion) of GS2 (the wild type). The trap and insertion PCR indicate the presence of
the trapped allele (samples 1, 2 and 4). Absence of a band indicates a wild type genotype (see
samples 3 and 5). The wild-type PCR indicates the presence of the wild-type allele. Absence of
a band would signify the loss of the wild-type allele.
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intercrossed the F1 heterozygotes. Using the PCR primers specific for exon 2 and intron
2 in the BubR1 gene, we found that the BubR1 homozygous mutation led to embryonic
lethality (table 1). It was during this work that other groups published similar results and
showed that in these nullizygous embryos, lethality was due to mitotic catastrophe and an
up-regulation of apoptosis (62).

Generation of BubR1/p53 Compound Mutants:
Since the embryonic lethality observed in BubR1 null animals was due to
apoptosis and a possible up-regulation of the tumor suppressor p53, a transcription factor
for several apoptotic genes, we hypothesized that the BubR1 nullizygotes could be
rescued in a p53 deficient background. To test this, we generated BubR1/p53 compound
mutants to determine if the loss of p53 would rescue this lethal phenotype. The BubR1
heterozygous offspring were crossed with p53 mutant mice to generate our compound
heterozygous mice. To determine if p53 deficiency rescued the embryonic lethality of
BubR1 nullizygotes, various crosses were done in which both mice were heterozygous
for BubR1 and deficient for p53 (tables 2a-c). Overall, during the course of 39 crosses,
243 mice were produced. Using the PCR genotyping strategy described above, it was
found that the progeny exhibited all the expected genotypes in their approximate ratios
with the exception of the BubR1 nullizygotes. This indicated that p53 deficiency does
not rescue the embryonic lethal phenotype observed in a BubR1 nullizygous animals.
Since p53 deficiency failed to rescue the lethality observed in the BubR1 nullizygotes, we
wanted to learn if the deficiency was able to delay the lethal phenotype during
embryogenesis. Since we ere unable to produce mice nullizygous for BubR1, and since
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Table 1: Embryonic lethality of BubR1 nullizygotes.

BubR1+/- X BubR1+/- [n=7]
BubR1 WT

BubR1 Het

BubR1 Null

11

16

0

This table shows the results of multiple BubR1 heterozygous pairings. Mice were genotyped for
BubR1 using the PCR strategies mentioned earlier. From these pairings no BubR1 nullizygous
progeny were generated. Other groups produced similar results and found that this lack of
nullizygous progeny was due to apoptosis and reabsorption of the nullizygous embryos at
embryonic day 6.5 (62).

39

Table 2: p53 deficiency does not rescue the lethality of the BubR1 nullizygotes.
a.
BubR1+/- p53+/- X BubR1+/- p53+/- [n=4]
BubR1Het/ BubR1 Wt/ BubR1 Wt/ BubR1 Het/ BubR1 Het/ BubR1 Het/ BubR1 Null / p53
p53 Wt
p53 Het
p53 Null
p53 Wt
p53 Het
p53 Null
Wt, Het, Null
2
4
1
1
12
4
0

b.
BubR1+/- p53+/- X BubR1+/- p53-/- [n=18]
BubR1 Wt/ BubR1 Wt/ BubR1 Het/ BubR1 Het/ BubR1 Null / p53
p53 Het
p53 Null
p53 Het
p53 Null
Het, Null
14
12
32
17
0

c.
BubR1+/- p53 -/- X BubR1+/- p53-/- [n=2]
BubR1 Wt/ BubR1 Het/
p53 Null
p53 Null
6
4

BubR1 Null /
p53 Null
0

A table showing the genotype of the crossed mice as well as the number of crosses [n] of each
type and the number of offspring produced for each possible genotype. Mice were genotyped
using the PCR and Southern blotting strategies mentioned previously. P53 deficiency was unable
to rescue the lethality of the BubR1 nullizygotes even if both parents were heterozygous (a), or if
one (b) or both parents (c) were nullizygous for p53.
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earlier studies have shown that p53 deficiency can delay embryonic lethality of DNA
damage response gene mutants (68, 69), we attempted to generate MEF lines nullizygous
for BubR1. Various crosses were set up and MEFs were generated from E10.5 and E13.5
day embryos as explained above. BubR1 nullizygous cell lines were not generated from
any of the crosses, indicating that p53 deficiency was unable to delay the lethal
phenotype at least up to E10.5 (table 3 and data not shown).

BubR1 Deficiency Enhances Tumor Formation in p53 Mutant Mice:
To determine the effect of the BubR1 and p53 gene deficiency on overall survival
and tumor formation we monitored the mutants and wild type littermates for a period of
two and a half years. Mice exhibiting morbidity and signs of tumor formation were
euthanized and autopsies were performed. The ages of the mice were recorded on a
spreadsheet and used to create survival curves for each genotype (figure 7). As shown in
the graph, the loss of one allele for either gene decreases the survivability of the mice and
the loss of one allele in both genes further decreases the survivability implying a
cumulative effect for the compound mutant. The wild-type mice survived the longest
with a median age of 104.8 weeks. With the loss of one allele for either BubR1 or p53,
survival decreased (63.1 weeks for the p53 heterozygous mutant and 70 weeks for the
BubR1 heterozygous mutant). For both of these single mutants, when compared to the
wild type, the survival was significantly different (P value= 0.0077 for the wild type
versus the BubR1 heterozygous mutant and P value= <0.0001 for the wild type versus the
p53 heterozygous mutant). When the compound heterozygous mutant was analyzed, it
was found that the survival was decreased further (50 weeks) and that this was also
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Table 3: p53 deficiency is unable to delay the lethal phenotype observed in BubR1
nullizygotes.

MEF Crosses: BubR1+/- p53+/- X BubR1+/- p53+/- [n=2]
BubR1 Wt/ BubR1 Wt/ BubR1 Wt/ BubR1 Het/ BubR1 Het/ BubR1 Het/ BubR1 Null / p53
p53 Wt

p53 Het

p53 Null

p53 Wt

p53 Het

p53 Null

Wt, Het. Null

1

*

*

2

2

6

0

A table of the MEF cell lines produced from two double heterozygous mutants. While no p53
single mutants were produced from these two crosses, these two cell lines were available through
previous work by the investigator. (*) Later crosses using mice from the colony produced MEF
lines including both the Wt/Het and Wt/Null genotypes. At both E10.5 and E13.5 there is no
generationof BubR1 nullizygous cell lines.
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Figure 7: Survival of wild type, heterozygous and compound heterozygous mutant mice. All
mice were of mixed inbred (C57Bl/6 X 129P2/OlaHsd) background. The percentages of tumorfree survivors are plotted as function of age in weeks (Prism 4 statistical software, GraphPad,
Software Inc. San Diego, CA). Animals were monitored for tumors, morbidity or spontaneous
death over a period of two and a half years (168 weeks). Moribund or tumor bearing mice were
sacrificed and necroposied. Tumors or tissues with abnormal morphology were subjected to
histopathological analysis to confirm their status as tumors.
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significant when compared to the wild-type (P value= <0.0001 for the compound mutant
versus the wild-type). However, it was also determined the survival curves of the single
mutation genotypes (BubR1+/+ p53+/-, and BubR1+/- p53+/+) were not significantly
different when compared to each other (P value= 0.1418). With this information it is
then important to make sure that the survival curve of the double mutation is significantly
different when compared to both of the single mutation genotypes. It was found that for
comparison to both of the single mutants, the survival curve of the double mutant was
significantly different (P value= 0.005 versus the BubR1+/+ p53+/- and P value= 0.0002 for
the BubR1+/- p53+/+). The two p53 nullizygous survival curves were also compared and
though not significantly different to one another (P value= 0.9755), they were significant
when compared to the other genotypes. However, with the complete loss of p53, the
genotype of BubR1 has no additive effect on the survivability due to the rapid induction
of lymphatic tumors in the p53 nullizygous background (figure 8).
The formalin-fixed samples mentioned above were then paraffin embedded and
made into slides for the pathologist to examine and verify the tumor presence and type.
The majority of the tumors observed were of lymphomas of the spleen and thymus.
While spleenic and thymic lymphomas are commonly seen in p53 deficient models, mice
deficient for BubR1 also showed the involvement of liver and lung tumors possibly due
to the metastasis of the primary lymphomas, something not seen in the p53 single
mutants (figures 9 and 10)
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Figure 8: Survival of BubR1 mutants in p53 nullizygous background. All mice were of mixed
inbred (C58BL/6 X 129SP2/OlaHsd) background. The percentages of tumor-free survivors are
plotted as function of age in weeks. Animals were monitored for tumors, morbidity or
spontaneous death over a period of 2.5 years (168 weeks). Moribund or tumor bearing mice were
sacrificed and necroposied. Tumors or enlarged tissues were subjected to histopathological
analysis to confirm their status as tumors.
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Tumor Spectrum of the Single and Compound Heterozygous Mice
BubR1+/+ p53+/- (n=7)

BubR1+/- p53+/+ (n=5)
20%

0%
29%

0%

42%
20%

60%

BubR1+/- p53+/- (n=17)

29%

6%
28%
22%

Legend
Lymphomas
Sarcomas
Osteosarcomas

Figure 9: Tumor spectrum of the single and compound

heterozygous mutants. The tumor spectrum is
consistent with historical data for the p53 heterozygotes.s

Carcinomas
Other

22%

22%
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Tumor Spectrum of the Single and Compound Nullizygous Mice

BubR1+/+ p53-/- (n=18)

BubR1+/- p53-/- (n=20)

6%

10%

5%

17%

77%

85%

Legend
Figure 10: Tumor Spectrum of the single and compound nullizygous mice.

The tumor spectrum is consistent for the p53 nullizygotes. There is no
observed shift in the tumor spectrum possibly due to the rapid induction
of spleenic and thymic lymphomas in the p53 nullizygous background.

Lymphomas
Sarcomas
Carcinomas
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Gene Dosage Effect of BubR1 During Tumorigenesis
To determine if there was a loss of heterozygosity for BubR1 in the compound
heterozygotes, we performed PCR analysis of the DNA isolated from the tumors. Of
the16 BubR1/p53 heterozygous mutants examined, none of the tumors had lost the wild
type allele. This indicates that the loss of a single copy of BubR1 gene was sufficient for
the tumorigenic phenotype observed in the compound mutants.

BubR1 Deficiency Enhances Cell Proliferation and Cell Transformation Potential:
To better understand the effects of BubR1 deficiency on cellular proliferation we
compared the cell growth kinetics of wild type and mutant MEFs. Single mutant and
compound mutant MEFs were used in cellular growth assays. Analysis of the growth
curves indicated that the loss of either the p53 or the BubR1 alleles resulted in an increase
in the proliferation capacity (figure 11). Furthermore, compound heterozygous cell lines
had an increased proliferation rate when compared to both the wild type and the single
heterozygous lines. Interestingly, in the case of the p53 nullizygous mutants, BubR1
deficiency had an additive effect on the cellular growth rate indicating that deficiency of
BubR1 allowed a growth advantage in the p53 nullizygous cell line.
Loss of tumor suppressor genes usually provides a growth advantage that can be
correlated to the ability of the cells to grow in sub-optimal conditions. To determine if
BubR1 deficiency synergized with the ability of p53 mutant cells, MEFs, we measured
the colony forming ability of these cells. Colony forming assays were performed using
the MEF cell lines generated. Consistent with the cell growth kinetic assays, we found
that the loss of BubR1 and p53 either alone or in
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Cell Count (X 10,000)

Growth Curve (125,000 cells seeded)
500
BubR1 Wt/ p53 WT
400

BubR1 Het/ p53 WT

300

BubR1 WT/ p53 Het

200

BubR1 Het/ p53 Het
BubR1 WT/ p53 Null

100

BubR1 Het/ p53 Null
0
0

1

2

3

4

5

Day

Figure 11: BubR1 and p53 Deficiency has a synergistic effect on cellular proliferation. This
representative graph shows the growth kinetics of the various BubR1/p53 genotypes and their
growth over 5 days. In each experiment (repeated 3 times) 125,000 cells were seeded onto each
plate.
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combination increased the colony forming potential (figure 12). Furthermore, our
preliminary analysis of BubR1 deficiency in p53 nullizygous MEFs indicated that the
BubR1 compound mutants (BubR1+/- p53-/-) were more susceptible to mitotic slippage
when treated with the spindle poison, nocodazole (data not shown).
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Number of Colonies
formed

CFU Assay
70
60
50
40
30
20
10
0

BubR1WT/p53 WT
BubR1 Het/p53 WT
BubR1 WT/p53 Het
BubR1 Het/p53 Het
BubR1 WT/p53 Null
BubR1Het/ p53 Null

1
2500 Cells plated initially

Figure 12: BubR1 and p53 deficiency has a synergistic effect in the transformation potential of
MEFs. This is a representative graph showing the CFU assay results, after nine days of growth,
based on the genotype of each cell line. In all the three experiments a similar trend was observed.
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IV. Discussion
Tumorigenesis is a multi-step process in which the mutation or loss of one gene is
usually insufficient to promote a cancer phenotype. However this single loss can provide
a growth advantage to cells and with time, start a domino effect of genetic loss in the
organism until a mutant cell line loses cell cycle controls resulting in uncontrolled
proliferation. This proliferation can then feedback on itself and enhance the risk of
genetic mutation that can ultimately lead to the formation of a tumor mass. In a subset of
colonic cancers, it was found that the mitotic spindle checkpoint gene BubR1 was
mutated and it was proposed that this mutation could lead to chromosomal instability and
an increased risk of tumorigenesis (43, 44). Following experiments showed that mouse
models deficient for BubR1 showed an increased susceptibility to carcinogen induced
tumor formation, anemia, and splenomegaly (61, 62). Additional studies have shown that
BubR1 deficiency increased the cancer formation susceptibility in a mouse background
known to be prone for colonic tumors (through a mutation of the Adenomatous polyposis
coli gene) (64).
The purpose of our project was to examine the effects of a combined BubR1/p53
deficiency as human cancers show a preponderance of p53 mutations along with a subset
showing mutations in the BUBR1 gene. Our work confirmed the results from others in
showing that the complete loss of BubR1 was embryonic lethal (61, 62). Additionally,
we showed that the loss of p53 was not able to rescue or significantly delay this lethality
during embryogenesis. It is possible that the loss of p53 may slightly delay the lethality
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of the BubR1 nullizygous embryos past the observed lethality from E6.5-E8.5 to E9.5,
but this will require further work to determine the embryonic lethality at that stage.
The tumor incidence and survival data of BubR1 mutants in the presence or
absence of p53 provide evidence that the loss of BubR1 leads to an increased mortality as
well as an alteration in the type of tumors observed. In previous work examining the
tumor incidence and lifespan of p53 deficient mouse models, it was found that the loss of
one allele leads to an increased incidence of tumorigenesis with a specificity for
osteosarcomas and soft tissue sarcomas by 15 months while a complete loss of the gene
leads to the formation of lymphomas within 6 months (70, 71). In the compound mutants
for BubR1 and p53, the earliest incidence of tumorigenesis was observed around 36
weeks with the mice having a median lifespan of 50 weeks. The tumor spectrum of these
mice was also different with the involvement of spleen, thymus, liver and lung tumors.
The induction of lung and liver tumors are rarely observed in the p53 mutants. We also
compared the survival of the p53 heterozygous and the BubR1 heterozygous and found
that there were no significant differences even though the median age of the p53
heterozygotes were 7 weeks earlier than the BubR1 heterozygotes. However comparison
of the survival data between the heterozygotes and the compound heterozygotes (p53+/BubR1+/-) showed a significant decrease in the median life span and an increase in the
tumor incidence of the compound mutants. A likely explanation of these results is that
with the additional mutation of BubR1 there is an increased incidence of chromosomal
instability and mitotic slippage and these two events lead to other genetic alterations and
an increase in tumorigenesis. This difference was not apparent in a p53 nullizygous
background due to the fact that a complete deficiency of p53 induces a rapid
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tumorigenesis phenotype that prevents the analysis of any additional effects of BubR1
deficiency.
To better understand the synergistic effects of BubR1 on p53 deficiency induced
tumorigenesis, we studied the phenotypes of the mutants at the cellular level. Analysis of
cell growth kinetics showed that while the single heterozygous mutants had similar
kinetics, the compound mutant cell lines had an increased growth rate. This is consistent
with the checkpoint role of both of the proteins during the cell cycle, which would confer
a growth advantage to the compound mutant. Furthermore, the increased cellular
proliferation rate of the compound heterozygotes translates to an enhanced tumorigenesis
phenotype at the organismal level. These results also verify that while p53 and BubR1
are primarily involved in separate checkpoint systems, the loss of both the checkpoints
leads to increased cell proliferation. If these two proteins worked together only in a
single checkpoint then the effects of the double mutant would not be additive but rather
would show the same growth curve to the single mutants. Interestingly, we observed
significant differences in the growth rates of compound mutants that were nullizygous for
p53 (p53-/- BubR1+/- and p53-/- BubR1+/+). This observation provides additional evidence
that the loss of BubR1 protein intensifies the effects of p53 loss during tumorigenesis.
We observed a similar trend in the colony forming assays in which the loss of BubR1
resulted in a higher transformation potential of the p53 heterozygotes and nullizygotes
(p53-/+ BubR1+/- and p53-/- BubR1+/-).
In our work we were able to generate a mouse model defective for two genes
involved in the regulation of various phases of the cell cycle. This work has confirmed
the results of previous studies in determining the effect of the BubR1 nullizygosity during
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embryogenesis and extended these observations to show that p53 deficiency can not
rescue the embryonic lethal phenotype in the BubR1 nullizygotes. Our results indicate
the importance of the BubR1 protein at earlier stages of mammalian development. In this
work, we have also shown for the first time, that the mutation of BubR1 alters the life
span and increases the incidence of tumorigenesis and these effects are amplified in a p53
deficient background. The synergistic effects of BubR1 deficiency on a p53 deficient
background are consistent with the recent finding that showed a role for the BubR1
protein in effecting a DNA damage response after treatment with DNA damaging agents
(58). The initial purpose of this study was to generate a mouse model for colon cancer
formation. However, our data suggests that the mutant mice generated so far are not
susceptible to colon cancers. The lack of colon cancers is possibly due to strain specific
differences of tumor susceptibilities seen in various inbred mouse strains (72). Based on
our experimental observations, we plan to back cross our BubR1 deficient mouse model
from the C57 BL/6 strain to the Balb/C strain. In addition, the progression of human
colon cancer requires additional mutations that involve the activation of the RAS
oncogene and the inactivation of the tumor suppressor genes p16 and APC. Therefore an
inherent disadvantage of our mouse model would be the requirement of additional
mutations. Nonetheless, our results suggest that the loss of the BubR1 gene can increase
the susceptibility of tumorigenesis in mice.
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